Taken together, these results suggest that crizotinib plus either afatinib or WZ4002 may overcome the resistance to reversible EGFR-TKIs of EGFR mutant lung cancer cells containing an EGFR gatekeeper mutation, Met gene amplification, and/or HGF overexpression. This evidence concerns the gene MET and lung carcinoma.